1275019-54-9

Upstream product

• 1208008-44-9 (S)-2-(5-ethynyl-1H-benzoimidazol-2-yl)-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1275034-50-8 C₁₆H₂₁BrN₂O₃ 
• 1208008-43-8 C₂₁H₂₉N₃O₂Si 
• 1208007-67-3 1,1-dimethylethyl (2S)-2-(5-bromo-1H-benzimidazol-2-yl)-1-pyrrolidinecarboxylate 
• 1228553-72-7 (2S)-1-tert-butoxycarbonyl-2-(2-amino-4-bromophenylaminoacyl)pyrrolidine 
• 1575-37-7 4-Bromo-benzene-1,2-diamine 
• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 

Downstream Products

• 1275034-58-6 C₂₄H₂₅N₅O 

Relevant academic research and scientific papers

HEPATITIS C VIRUS INHIBITORS

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with said compounds.